OPEN END TURBO SHORT - LABORATORY CO. OF AMER. HLD | Market Closed - Börse Stuttgart 20:38:33 17/05/2024 BST | ||
| 3.77 EUR | +12.54% |
|
| Current month | -16.78% | ||
| 1 month | -19.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about LABORATORY CORPORATION OF AMERICA HOLDINGS
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 3.77 | +12.54% |
| 16/05/24 | 3.35 | -3.46% |
| 15/05/24 | 3.47 | -7.71% |
| 14/05/24 | 3.76 | +0.80% |
| 13/05/24 | 3.73 | -7.90% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 08:38 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| Issuer | Morgan Stanley |
| WKN | ME4T5M |
| ISIN | DE000ME4T5M0 |
| Date issued | 06/12/2023 |
| Strike | 250.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.86 € |
|---|---|
| Lowest since issue | 1.69 € |
Company Profile
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows:
- clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services;
- development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies.
Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Sector
-
Ratings for Laboratory Corporation of America Holdings
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Laboratory Corporation of America Holdings
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
210.6
USD
Average target price
239.7
USD
Spread / Average Target
+13.81%
- Stock Market
- Certificates
- Certificat
